FrancophonIA/ELRC3.0 huggingface dataset:
Latvian: Pamatojoties uz laboratoriskajiem izmeklējumiem lielā klīniskajā pētījumā pārejoša, asimptomātiska kalcija līmeņa pazemināšanās asinīs (mazāk par 2,10 mmol/l) attīstījās 2,3% pacientu, kuri tika ārstēti ar Zoledronic acid Teva Pharma, salīdzinot ar 21% pacientu, kuri tika ārstēti ar Zoledronic acid Teva Pharma Pedžeta slimības pētījumos.
Icelandic: Rannsóknaniðurstöður sýna að tímabundin einkennalaus kalsíumlækkun, niður fyrir eðlileg viðmiðunarmörk (undir 2,10 mmól/l) átti sér stað hjá 2,3% sjúklinga sem fengu meðferð með zoledronsýru í stórri klínískri rannsókn, samanborið við 21% sjúklinga sem fengu meðferð með zoledronsýru í rannsóknunum á Pagetssjúkdómi.
Latvian: Pirms Zoledronic acid Teva Pharma terapijas pārtraukšanas Ja Jūs apsverat Zoledronic acid Teva Pharma terapijas pārtraukšanu, lūdzu, ierodieties uz nākamo vizīti un apspriediet to ar savu ārstu.
Icelandic: Áður en meðferð með Zoledronic acid Teva Pharma er hætt Ef hugleitt er að hætta á meðferð með Zoledronic acid Teva Pharma, ætti að ræða það við lækninn í næsta viðtalstíma.
Latvian: Pēc atvēršanas: 24 stundas temperatūrā 2°C - 8°C.
Icelandic: Fyrnist Rofin pakkning: 24 klst. við 2°C - 8°C.
Latvian: Šo blakusparādību rašanās iespēja mazinās līdz ar katru nākamo Zoledronic acid Teva Pharma devu.
Icelandic: Líkurnar á að fá þessar aukaverkanir minnka með áframhaldandi skömmtum af Zoledronic acid Teva Pharma.
Latvian: Ārstēšanās ar Zoledronic acid Teva Pharma laikā Jums jānodrošina laba mutes dobuma higiēna (ieskaitot regulāru zobu tīrīšanu) un jāveic regulāras zobu pārbaudes.
Icelandic: Meðan á meðferð með Zoledronic acid Teva Pharma stendur skaltu viðhalda góðri tannheilsu (þar með talið reglulegri tannburstun) og fara reglulega í skoðun til tannlæknis.
Latvian: Zoledronic acid Teva Pharma terapija strauji samazināja kaulu vielmaiņas ātrumu no paaugstināta līmeņa pēc-menopauzē ar zemāko rezorbcijas marķieru līmeni pēc 7 dienām un zemāko veidošanās marķieru līmeni pēc 12 nedēļām.
Icelandic: Meðferð með zoledronsýru dró hratt úr umsetningu beina, úr hækkuðum gildum eftir tíðahvörf, en fram kom að beineyðingargildi voru í lágmarki eftir 7 daga og beinmyndunargildi eftir 12 vikur.
Latvian: Zoledronic acid Teva Pharma nozīmīgi mazināja vienu vai vairāku jaunu skriemeļu lūzumu sastopamību trīs gadu laikā un jau pēc pirmā gada (skatīt 2. tabulu).
Icelandic: Zoledronsýra dró marktækt úr tíðni eins eða fleiri nýrra hryggjarliðabrota á þriggja ára tímabili og svo fljótt sem eftir eitt ár (sjá töflu 2).
Latvian: Zoledronic acid Teva Pharma lieto arī pacientiem, kuriem nesen nelielas traumas (piemēram, kritiena) rezultātā bijis gūžas kaula lūzums, un tādēļ pastāv palielināts atkārtotu kaulu lūzumu risks.
Icelandic: Zoledronic acid Teva Pharma er einnig notað handa sjúklingum sem hafa mjaðmagrindarbrotnað nýlega vegna minniháttar áverka, svo sem falls og eru því í hættu á beinbrotum í kjölfarið.
Latvian: Šķīdums infūzijām 100 ml
Icelandic: Innrennslislyf, lausn 100 ml
Latvian: Transportlīdzekļu vadīšana un mehānismu apkalpošana Ja pēc Zoledronic acid Teva Pharma ievadīšanas Jums rodas reibonis, nevadiet transportlīdzekļus un neapkalpojiet mehānismus līdz brīdim, kad jūtaties labāk.
Icelandic: Ef þig sundlar meðan á meðferð með Zoledronic acid Teva Pharma stendur, máttu ekki aka eða nota vélar fyrr en þér líður betur.
Latvian: Zoledronic acid Teva Pharma ārējais izskats un iepakojums Zoledronic acid Teva Pharma ir dzidrs un bezkrāsains šķīdums.
Icelandic: Lýsing á útliti Zoledronic acid Teva Pharma og pakkningastærðir Zoledronic acid Teva Pharma er tær og litlaus lausn.
Latvian: Katra pudele satur 100 ml šķīduma.
Icelandic: Hvert glas inniheldur 100 ml af lausn.
Latvian: Sievietes reproduktīvā vecumā Zoledronic acid Teva Pharma nav ieteicams lietot sievietēm reproduktīvā vecumā.
Icelandic: Konur á barneignaraldri Notkun Zoledronic acid Teva Pharma er ekki ráðlögð hjá konum á barneignaraldri.
Latvian: Klīnisko lūzumu, tajā skaitā skriemeļu, neskriemeļu un gūžas kaulu lūzumu sastopamība tika izvērtēta pētījumā, kurā piedalījās 2 127 vīrieši un sievietes vecumā no 50 līdz 95 gadiem (vidējais vecums 74,5 gadi) ar nesenu (līdz 90 dienām) nelielas traumas izraisītu gūžas kaula lūzumu, un kuri vidēji 2 gadus bija lietojuši pētījuma zāles.
Icelandic: Lagt var mat á tíðni klínískra brota, þar með talið brota á hryggjarlið, annarra brota en á hryggjarlið og mjaðmarbrota, hjá 2.127 körlum og konum á aldrinum 50-95 ára (meðalaldur 74,5 ár) með nýlegt (innan 90 daga) mjaðmarbrot vegna minniháttar áverka, sem fylgt var eftir í að meðaltali 2 ár á rannsóknarmeðferð.
Latvian: Eiropas Zāļu aģentūra atbrīvojusi no pienākuma iesniegt pētījumu rezultātus ar atsauces zāles, kas satur zoledronskābi, visās pediatriskās populācijas apakšgrupās pacientiem ar Pedžeta kaulu slimību, osteoporozi sievietēm pēc menopauzes ar palielinātu lūzumu risku, osteoporozi vīriešiem ar palielinātu lūzumu risku, un klīnisko kaulu lūzumu profilaksei vīriešiem un sievietēm pēc gūžas kaula lūzuma (informāciju par lietošanu bērniem skatīt 4.2. apakšpunktā).
Icelandic: Lyfjastofnun Evrópu hefur fallið frá kröfu um að lagðar verði fram niðurstöður úr rannsóknum á samanburðarlyfinu sem iniheldur zoledronsýru hjá öllum undirhópum barna við Pagetssjúkdómi í beinum, beinþynningu hjá konum eftir tíðahvörf sem eru í aukinni hættu á beinbrotum, beinþynningu hjá körlum sem eru í aukinni hættu á beinbrotum og fyrirbyggingu klínískra brota eftir mjaðmarbrot hjá konum og körlum (sjá upplýsingar í kafla 4.2 um notkun handa börnum).
Latvian: Informācijas paketē pacientam papildus jāiekļauj sekojoši dokumenti:
Icelandic: Að auki skulu eftirtalin skjöl vera hluti af upplýsingapakkanum fyrir sjúklinginn:
Latvian: EU/1/12/772/003 EU/1/12/772/004
Icelandic: EU/1/12/772/004
Latvian: Kas ir Zoledronic acid Teva Pharma un kādam nolūkam tās lieto Kas Jums jāzina pirms Zoledronic acid Teva Pharma ievadīšanas Kā Zoledronic acid Teva Pharma tiek ievadītas Iespējamās blakusparādības
Icelandic: Upplýsingar um Zoledronic acid Teva Pharma og við hverju það er notað Áður en byrjað er að nota Zoledronic acid Teva Pharma Hvernig nota á Zoledronic acid Teva Pharma
Latvian: Zoledronic acid Teva Pharma satur aktīvo vielu zoledronskābi.
Icelandic: Zoledronic acid Teva Pharma inniheldur virka efnið zoledronsýru.
Latvian: Mikrodatortomogrāfijas (μDT) analīzes pierādīja paaugstinātu trabekulāro kaulu tilpumu un trabekulārās kaula arhitektonikas saglabāšanos pacientiem, kas ārstēti ar zoledronskābi, salīdzinot ar placebo.
Icelandic: Örtölvusneiðmyndargreining (CT) sýndi aukningu á rúmmáli bjálkabeins (trabecular bone) og verndun bjálkabeinsbyggingar hjá sjúklingum í meðferð með zoledronsýru samanborið við lyfleysu.
Latvian: Īpaši svarīgi tas ir gados veciem cilvēkiem (≥65 g.v.) un pacientiem, kuri saņem diurētiskus līdzekļus.
Icelandic: Þetta er sér í lagi mikilvægt hjá öldruðum (≥ 65 ára) og hjá sjúklingum í þvagræsimeðferð.
Latvian: Aizkavētu gūžas kaula lūzumu dzīšanas gadījumu sastopamība zoledronskābes un placebo grupās bija līdzīga - attiecīgi (34 [3,2%]) un (29 [2,7%]).
Icelandic: Tíðni seinkunar á því að mjaðmarbrot greru var sambærileg fyrir zoledronsýru (34 [3,2%]) og lyfleysu
Latvian: Multipaka: 5 maisi ar 100 ml Multipaka: 10 maisi ar 100 ml
Icelandic: Innrennslislyf, lausn Fjölpakkning: 5 pokar með 100 ml Fjölpakkning:
Latvian: Tādēļ šie rezultāti neļauj izdarīt secinājumus par Zoledronic acid Teva Pharma ietekmi uz cilvēku fertilitāti.
Icelandic: Þessar niðurstöður komu því í veg fyrir að hægt væri að ákvarða endanlega hver áhrif zoledronsýru á frjósemi hjá mönnum eru.
Latvian: - Pēc pudeles atvēršanas zāles jāizmanto nekavējoties, lai izvairītos no mikrobioloģiskā piesārņojuma.
Icelandic: - Eftir að glasið hefur verið rofið skal nota lyfið strax til að koma í veg fyrir örverumengun.
Latvian: Svarīgi, lai dažas stundas pirms Zoledronic acid Teva Pharma devas ievadīšanas Jūs izdzertu vismaz divas glāzes šķidruma (piemēram, ūdens), kā to norādījis Jūsu veselības aprūpes speciālists.
Icelandic: Mikilvægt er að þú drekkir að minnsta kosti 2 glös af vökva (svo sem vatni) innan nokkurra klukkustunda áður en þú færð Zoledronic acid Teva Pharma, samkvæmt ráðleggingum heilbrigðisstarfsmannsins.
Latvian: Lielākā daļa šo nevēlamo blakusparādību attīstās pirmo trīs dienu laikā pēc Zoledronic acid Teva Pharma lietošanas.
Icelandic: Flestar þessara aukaverkana koma fram á fyrstu þremur dögunum eftir gjöf zoledronsýru.
Latvian: Saņemti ziņojumi par žokļa osteonekrozes gadījumiem galvenokārt vēža slimniekiem, kuri ārstēti ar zālēm, kas inhibē kaulu resorbciju, ieskaitot zoledronskābi (skatīt 4.4. apakšpunktu).
Icelandic: Greint hefur verið frá beindrepi í kjálka, einkum hjá krabbameinssjúklingum sem fá meðferð með lyfjum sem hamla beineyðingu, þ. á m. zoledronsýru (sjá kafla 4.4).
Latvian: Zoledronic acid Teva Pharma ievada caur ventilētu infūzijas sistēmu un lēnām ar nemainīgu infūzijas ātrumu.
Icelandic: Zoledronic acid Teva Pharma er gefið með innrennsli í bláæð, um innrennslislögn með ventli, hægt og með jöfnum innrennslishraða.
Latvian: Tās nedrīkst sajaukt (lietot maisījumā) vai ievadīt intravenozi kopā ar citām zālēm.
Icelandic: Hvorki má blanda því við nein önnur lyf né gefa það í bláæð með neinum öðrum lyfjum.
Latvian: Retāk (var attīstīties mazāk nekā 1 no 100 cilvēkiem)
Icelandic: Sjaldgæfar: geta komið fyrir hjá allt að 1 af hverjum 100 einstaklingum
Latvian: Nevertebrāls lūzums (1) *p-vērtība <0,001, **p-vērtība <0,0001 (1) izņemot rokas un kājas pirkstu un sejas kaulu lūzumus (2) ieskaitot klīniskus torakālo un klīniskus lumbālo skriemeļu lūzumus
Icelandic: Önnur brot en hryggjarliðabrot (1) *p-gildi < 0,001, **p-gildi < 0,0001 (1) Fingur-, tá- og andlitsbrot undanskilin.
Latvian: - Zoledronic acid Teva Pharma 5 mg šķīdums infūzijām ir gatavs lietošanai.
Icelandic: - Zoledronic acid Teva Pharma 5 mg innrennslislyf, lausn er tilbúin til notkunar.
Latvian: • Informācija, ka saistībā ar Zoledronic acid Teva Pharma ievadīšanu ir ieteicama o Nepieciešamība nodrošināt adekvāta kalcija un D vitamīna uzņemšanu, ievērot atbilstošu fizisko aktivitāti, aizliegumu smēķēt un veselīgu diētu o Nopietnu blakusparādību galvenās pazīmes un simptomi o Kad jāmeklē steidzama veselības aprūpes speciālista palīdzība
Icelandic: o Mikilvægi fullnægjandi kalsíum- og D-vítamín uppbótarmeðferðar, viðeigandi líkamshreyfinga, reykleysis og heilsusamlegs mataræðis o Hvenær leita eigi til heilbrigðisþjónustu
Latvian: Apkopojot rezultātus, 6 mēnešu laikā zoledronskābei un risedronātam tika novērota līdzīgu sāpju smaguma pakāpes un to radīto traucējumu mazināšanās, salīdzinot ar sākotnējo līmeni.
Icelandic: Í sameinuðum upplýsingum sást eftir 6 mánuði svipuð minnkun í skori alvarleika verkja og áhrifa verkja á daglegt líf, samanborið við upphafsgildi, fyrir zoledronsýru og risedronat.
Latvian: - Jūs iepriekš esat ārstēts ar bisfosfonātiem (lieto, lai ārstētu vai novērstu kaulu bojājumus); - Jūs lietojat zāles, ko sauc par kortikosteroīdiem (piemēram, deksametazonu);
Icelandic: - þú ert á meðferð með lyfjum sem kallast barksterar (svo sem prednisolon eða dexamethason); - þú ert með krabbamein.
Latvian: Turklāt pacientiem ar Pedžeta slimību noteikti ieteicams papildus lietot pietiekami daudz kalcija, kas atbilst vismaz 500 mg kalcija divreiz dienā, vismaz 10 dienas pēc Zoledronic acid Teva Pharma ievadīšanas (skatīt 4.2. apakšpunktu).
Icelandic: Einnig er eindregið mælt með fullnægjandi kalsíumuppbót, hjá sjúklingum með Pagetssjúkdóm, sem samsvarar að minnsta kosti 500 mg af kalsíum tvisvar sinnum á dag, í að minnsta kosti 10 daga eftir notkun Zoledronic acid Teva Pharma (sjá kafla 4.2).
Latvian: No mikrobioloģiskā viedokļa zāles būtu jāizlieto nekavējoties.
Icelandic: Frá örverufræðilegu sjónarhorni skal nota lyfið strax.
Latvian: Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97007-0
Icelandic: Österreich ratiopharm Arzenimittel Vertriebs-GmbH
Latvian: Kas ir Zoledronic acid Teva Pharma un kādam nolūkam tās lieto
Icelandic: Upplýsingar um Zoledronic acid Teva Pharma og við hverju það er notað
Latvian: Neskriemeļa lūzums (1) *p-vērtība <0,05, **p-vērtība <0,01 (1) Izņemot roku un kāju pirkstu un sejas kaulu lūzumus (2) Ietverot klīniskus mugurkaula krūšu daļas un klīniskus mugurkaula jostas daļas skriemeļu lūzumus
Icelandic: *p-gildi < 0,05, **p-gildi < 0,01 (1) Fingur-, tá- og andlitsbrot undanskilin.
Latvian: ZĀĻU FORMA UN SATURS Šķīdums infūzijām 1 pudele ar 100 ml.
Icelandic: Innrennslislyf, lausn 1 glas með 100 ml.
Latvian: Nav zināms (blakusparādību biežumu nevar noteikt pēc pieejamajiem datiem) Sāpes mutē un/vai sāpes žoklī, pietūkums vai nedzīstošas čūlas mutē vai žoklī, izdalījumi, nejutīgums vai smaguma sajūta žoklī, vai zobu izkrišana; šie simptomi var liecināt par žokļa kaulu bojājumiem (osteonekrozi).
Icelandic: Tíðni ekki þekkt (ekki hægt að áætla tíðni út frá fyrirliggjandi gögnum) Verkur í munni og/eða kjálka, þroti eða sár í munnholi eða kjálka gróa ekki, útferð úr sárum,, dofi eða þyngslatilfinning í kjálka eða tannlos.
Latvian: Galvassāpes, reibonis Letarģija, parestēzija, miegainība, trīce, sinkope, garšas sajūtas pārmaiņas
Icelandic: Drungi, húðskynstruflanir, svefnhöfgi, skjálfti, yfirlið, bragðskynstruflanir
Latvian: Farmakoterapeitiskā grupa: Zāles, kas ietekmē kaulu struktūru un mineralizāciju, bisfosfonāti, ATĶ kods: M05BA08
Icelandic: Lyf við sjúkdómum í beinum, bisfosfonöt, ATC flokkur:
Latvian: Kā sagatavot un ievadīt Zoledronic acid Teva Pharma
Icelandic: Hvernig á að undirbúa og gefa Zoledronic acid Teva Pharma
Latvian: Osteoporozes klīniskajos pētījumos kreatinīna klīrensa pārmaiņas (ko mērīja katru gadu pirms devas lietošanas) un nieru mazspējas un nieru darbības traucējumu sastopamība trīs gadu laikā Zoledronic acid Teva Pharma un placebo grupās bija līdzīga.
Icelandic: Í klínískri rannsókn á beinþynningu var breytingin á kreatininúthreinsun (mæld árlega áður en lyfið var gefið), tíðni nýrnabilunar og skerðingar á nýrnastarfsemi sambærileg hjá þeim sem fengu zoledronsýru og þeim sem fengu lyfleysu á þriggja ára tímabili.
Latvian: • pieaugušiem vīriešiem ar palielinātu lūzumu risku, kā arī cilvēkiem ar nesenu nelielas traumas izraisītu gūžas kaula lūzumu.
Icelandic: hjá fullorðnum körlum sem eru í aukinni hættu á beinbrotum, þar með talið eftir nýlegt mjaðmarbrot vegna minniháttar áverka.
Latvian: Pacientiem ar Pedžeta slimību noteikti ieteicams papildus lietot pietiekami daudz kalcija, kas atbilst vismaz 500 mg kalcija divreiz dienā, vismaz 10 dienas pēc Zoledronic acid Teva Pharma ievadīšanas (skatīt 4.4. apakšpunktu).
Icelandic: Eindregið er mælt með fullnægjandi kalsíumuppbót, hjá sjúklingum með Pagetssjúkdóm, sem samsvarar að minnsta kosti 500 mg af kalsíum tvisvar sinnum á dag, í að minnsta kosti 10 daga eftir notkun Zoledronic acid Teva Pharma (sjá kafla 4.4).
Latvian: Zoledronic acid Teva Pharma 5 mg šķīdumu infūzijām maisos nedrīkst sajaukt (lietot maisījumā) vai ievadīt intravenozi kopā ar jebkādām citām zālēm, tas ir jāievada caur atsevišķu ventilētu infūzijas līniju ar vienmērīgu infūzijas ātrumu.
Icelandic: Hvorki má blanda Zoledronic acid Teva Pharma við önnur lyf né gefa það í bláæð með öðrum lyfjum og lyfið verður að gefa um aðskilda innrennslislögn með ventli, með jöfnum innrennslishraða.
Latvian: Tā kā
Icelandic: A.
Latvian: Taču atzina, ka dažiem pacientiem varētu būt efektīva mazāka 5 mg deva.
Icelandic: Minni skammturinn, 5 mg, gæti gagnast sumum sjúklingum.
Latvian: Taču populācijas līmenī nejaušinātos pētījumos pārliecinoši pierādījumi bija iegūti vienīgi par zolpidēma 10 mg devas iedarbīgumu.
Icelandic: Slembiröðuðu rannsóknirnar sýndu aðeins fram á virkni 10 mg zolpidem.
Latvian: Tādēļ PRAC uzskatīja, ka ieteikumos par devām jāiekļauj norādījumi, ka zolpidēms jālieto vienā reizes devā tieši pirms gulētiešanas un to nedrīkst lietot atkārtoti tās pašas nakts laikā.
Icelandic: Zolpidem á að taka í einum skammti til inntöku að kvöldi rétt fyrir svefn og ekki á að taka annan skammt sömu nótt.
Latvian: Zinātniskie secinājumi un reģistrācijas apliecību nosacījumu izmaiņu pamatojums
Icelandic: 4.4 Sérstök varnaðarorð og varúðarreglur við notkun
Latvian: II pielikums
Icelandic: Fylgiseðill
Latvian: Zinātniskie secinājumi
Icelandic: Flogaveikilyf
Latvian: Building Sofia Tower Sofia 1303
Icelandic: Sofia Tower Sofia 1303
Latvian: Evropská 846/176a 160 00 Prague 6 - Vokovice Čehijas Republika
Icelandic: Evropská 846/176a 160 00 Prague 6 - Vokovice Czech Republic
Latvian: Teva Magyarország Zrt Repülőtéri út 5.
Icelandic: Ungverjaland Teva Magyarország Zrt Repülőtéri út 5.
Latvian: 1800 1800ilvoorde Beļģija
Icelandic: 1800 1800ilvoorde Belgium
Latvian: 83-200 Starogard Gdański Polija
Icelandic: 83-200 Starogard Gdański Poland
Latvian: ExtractumPharma zRt.
Icelandic: Ungverjaland ExtractumPharma zRt.
Latvian: 167 14 Bromma Zviedrija
Icelandic: 167 14 Bromma Sweden
Latvian: 2625-099 Povoa de Santa Iria Portugāle
Icelandic: 2625-099 Povoa de Santa Iria Portugal
Latvian: Verovškova 57, 1000 Ljubljana, Slovēnija
Icelandic: Verovškova 57, 1000 Ljubljana, Slovenia
Latvian: Orion Corporation Orionintie 1/A FI-02200 Espoo Somija
Icelandic: Orion Corporation Orionintie 1/A FI-02200 Espoo Finland
Latvian: SVUS Pharma a.s., Smetanovo nábřeží 1238/20a 500 02 Hradec Králové Čehijas Republika
Icelandic: SVUS Pharma a.s., Smetanovo nábřeží 1238/20a 500 02 Hradec Králové Czech Republic
Latvian: Cork, Īrija
Icelandic: Cork, Ireland
Latvian: Sector 5, Bucureşti, Rumānija
Icelandic: Sector 5, Bucureşti, România
Latvian: Mylan AB, Ynglingagatan 14, 10435 Stockholm, Zviedrija.
Icelandic: Mylan AB, Ynglingagatan 14, 10435 Stockholm, Sweden.
Latvian: 3542 DR Utrecht The Nīderlande
Icelandic: 3542 DR Utrecht The Netherlands
Latvian: 104 35 Stockholm Zviedrija
Icelandic: 104 35 Stockholm Sweden
Latvian: Rua Chanceler-Mor 11 R/c Frt. Cacem
Icelandic: Rua Chanceler-Mor 11 R/c Frt.
Latvian: 4879 AC ETTEN LEUR Nīderlande
Icelandic: 4879 AC ETTEN LEUR The Netherlands
Latvian: Actavis A/S Sucursal Rua Virgílio Correia, 11 - A 1600-219 Lisboa Portugāle
Icelandic: Actavis A/S Sucursal Rua Virgílio Correia, 11 - A 1600-219 Lisboa
Latvian: EGIS Gyógyszergyár Nyrt.
Icelandic: Ungverjaland EGIS Gyógyszergyár Nyrt.
Latvian: Tipperary Īrija
Icelandic: Tipperary Ireland
Latvian: Meda Pharma Hungary Kft Váci út 91.
Icelandic: Ungverjaland Meda Pharma Hungary Kft Váci út 91.
Latvian: Edvard Thomsens Vej 14 DK-2300 Köpenhamn S Dānija
Icelandic: Edvard Thomsens Vej 14 DK-2300 Köpenhamn S Denmark
Latvian: 2003 RN Haarlem PAYS-BAS Nīderlande
Icelandic: 2003 RN Haarlem PAYS-BAS The Netherlands
Latvian: 30-529 Kraków Polija
Icelandic: 30-529 Kraków Poland
Latvian: 64295 Darmstadt Vācija
Icelandic: 64295 Darmstadt Germany
Latvian: 1500 GB Zaandam The Nīderlande
Icelandic: 1500 GB Zaandam The Netherlands
Latvian: 13500 Hämeenlinna Somija
Icelandic: 13500 Hämeenlinna Finland
Latvian: Meda AB, Pipers väg 2A, Box 906, SE-170 09, Zviedrija
Icelandic: Meda AB, Pipers väg 2A, Box 906, SE-170 09, Sweden
Latvian: Vitabalans Oy Varastokatu 8
Icelandic: Þýskaland Vitabalans Oy Varastokatu 8
Latvian: 2794-038 Carnaxide Portugāle
Icelandic: 2794-038 Carnaxide Portugal
Latvian: LYFIS ehf., Grensásvegur 22, 108 Reykjavík, Islande
Icelandic: LYFIS ehf., Grensásvegur 22, 108 Reykjavík, Iceland
Latvian: 1186 DM AMSTELVEEN Nīderlande
Icelandic: 1186 DM AMSTELVEEN The Netherlands
Latvian: Aurobindo Pharma (Portugāle), Unipessoal Lda.
Icelandic: Aurobindo Pharma (Portugal), Unipessoal Lda.
Latvian: Labesfal Genéricos, S.A Avenida Dr. Afonso Costa, 1370 3465-051 Campo de Besteiros Portugāle
Icelandic: Labesfal Genéricos, S.A Avenida Dr. Afonso Costa, 1370 3465-051 Campo de Besteiros Portugal
Latvian: Tomás Ribeiro, 43 - Bloco 2, 3º F - Edifício Neopark 2790-221 Carnaxide Portugāle
Icelandic: Tomás Ribeiro, 43 - Bloco 2, 3º F - Edifício Neopark 2790-221 Carnaxide Portugal
Latvian: Ronda Isaac Peral, 6 Parque Tecnológico 46980 Paterna (Valencia)
Icelandic: GENERFARMA, S.L. Ronda Isaac Peral, 6 Parque Tecnológico 46980 Paterna (Valencia) SPAIN
Latvian: Meda Norge, P.O.BOX 194, 1371 ASKER, Norvēģija
Icelandic: Meda Norge, P.O.BOX 194, 1371 ASKER, Norway
Latvian: Largo Umberto Boccioni, 1, Origgio, Varese - 21040 Itālija
Icelandic: Largo Umberto Boccioni, 1, Origgio, Varese - 21040 Italy
Latvian: ZYDUS FRANCE 25, rue des Peupliers ZAC Les Hautes Pâtures - Parc d'Activités des Peupliers 92000 Nanterre FRANCIJA
Icelandic: Frakkland ZYDUS FRANCE 25, rue des Peupliers ZAC Les Hautes Pâtures - Parc d'Activités des Peupliers 92000 Nanterre FRANCE
Latvian: Lielbritānija Amneal Pharma Europe Limited, 70 Sir John Rogerson's Quay, Dublin 2, Īrija
Icelandic: Amneal Pharma Europe Limited, 70 Sir John Rogerson's Quay, Dublin 2, Ireland
Latvian: Sanofi-Aventis Ireland Limited T/A Sanofi, Citywest Business Campus, Dublin 24, Īrija
Icelandic: Sanofi-Aventis Ireland Limited T/A Sanofi, Citywest Business Campus, Dublin 24, Ireland
Latvian: Sanofi-Aventis Deutschland GmbH Industriepark Höchst, Gebäude K703
Icelandic: Þýskaland Sanofi-Aventis Deutschland GmbH Industriepark Höchst, Gebäude K703
Latvian: Actavis Norway AS, P.O.BOX 409, 0213 Skoyen, OSLO, Norvēģija
Icelandic: Actavis Norway AS, P.O.BOX 409, 0213 Skoyen, OSLO, Norway
Latvian: IOULIA AND IRENE TSETI PHARMACEUTICAL LABORATORIES ABEE, INTERMED ABEE, Kalyftaki 27, Kifissia 14564 Grieķija
Icelandic: IOULIA AND IRENE TSETI PHARMACEUTICAL LABORATORIES ABEE, INTERMED ABEE, Kalyftaki 27, Kifissia 14564
Latvian: 3752 LB BUNSCHOTEN Nīderlande
Icelandic: 3752 LB BUNSCHOTEN The Netherlands
Latvian: SANOFI-AVENTIS AEBE 348 SYNGROU AVENUE, BUILDING A, KALLITHEA 17674
Icelandic: Grikkland SANOFI-AVENTIS AEBE 348 SYNGROU AVENUE, BUILDING A, KALLITHEA 17674
Latvian: Poligono Industrial Areta .Huarte-Pamplona (Navarra)
Icelandic: Huarte-Pamplona (Navarra)
Latvian: Frederic Mompou, 5 , Sant Just Desvern (Barcelona).
Icelandic: LABORATORIO STADA, S.L. Frederic Mompou, 5 , Sant Just Desvern (Barcelona).
Latvian: ARROW GENERIQUES 26, avenue Tony Garnier 69007 Lyon Francija
Icelandic: Frakkland ARROW GENERIQUES 26, avenue Tony Garnier 69007 Lyon France
Latvian: Orifarm Generics A/S Energivej 15 POB 69 DK-5260 Odense S Dānija
Icelandic: Orifarm Generics A/S Energivej 15 POB 69 DK-5260 Odense S Denmark
Latvian: McDermott Laboratories Ltd t/a Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Īrija
Icelandic: McDermott Laboratories Ltd t/a Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland
Latvian: Latvija sanofi-aventis Latvia SIA, Kr.Valdemara 33-8 Riga, LV 1010, Latvija
Icelandic: Lettland sanofi-aventis Latvia SIA, Kr.Valdemara 33-8 Riga, LV 1010, Latvia
Latvian: 1. Budapest 1056 Ungārija
Icelandic: Budapest 1056 Hungary
Latvian: Pliva Hrvatska d.o.o., Prilaz baruna Filipovića 25, Zagreb, Horvātija
Icelandic: Pliva Hrvatska d.o.o., Prilaz baruna Filipovića 25, Zagreb, Croatia
Latvian: Rua João de Deus, 19 2700-487 Amadora Portugāle
Icelandic: Generis Farmacêutica, S.A. Rua João de Deus, 19 2700-487 Amadora Portugal
Latvian: Camí Real, 51-57 Palau-solita i Plegamans (Barcelona).
Icelandic: PHARMAGENUS, S.A. Avda. Camí Real, 51-57 Palau-solita i Plegamans (Barcelona).
Latvian: Sandoz d.o.o., Maksimirska 120, Zagreb, 1000, Horvātija
Icelandic: Sandoz d.o.o., Maksimirska 120, Zagreb, 1000, Croatia
Latvian: Sanofi Aventis Norge Strandveien 15, 1366 Lysaker, Norvēģija
Icelandic: Sanofi Aventis Norge Strandveien 15, 1366 Lysaker, Norway
Latvian: Genthon GmbH Groesbeeker Weg, 1 D-47559 Kranenburg Vācija
Icelandic: Genthon GmbH Groesbeeker Weg, 1 D-47559 Kranenburg Germany
Latvian: Meda Oy Vaisalantie 4 02130 Espoo Somija
Icelandic: Oy Vaisalantie 4 02130 Espoo Finland
Latvian: Actavis Deutschland GmbH & Co.KG Willy-Brandt-Allee 2
Icelandic: Þýskaland Actavis Deutschland GmbH & Co.KG Willy-Brandt-Allee 2
Latvian: Meda AS, Solvang 8, DK-3450 Allerød, Dānija
Icelandic: Meda AS, Solvang 8, DK-3450 Allerød, Denmark
Latvian: MEDA PHARMA Chaussee de la Hulpe 166 1170 Watermael-Boitsfort Beļģija
Icelandic: MEDA PHARMA Chaussee de la Hulpe 166 1170 Watermael-Boitsfort Belgium
Latvian: Krka - farma d.o.o., Radnička cesta 48, Zagreb, Horvātija
Icelandic: Krka - farma d.o.o., Radnička cesta 48, Zagreb, Croatia
Latvian: Edifícios Azevedos - Estrada Nacional 117-2, Alfragide 2614-504 Amadora Portugāle
Icelandic: Edifícios Azevedos - Estrada Nacional 117-2, Alfragide 2614-504